Tags : $1.6B

Bristol-Myers (BMS) Divests its UPSA Consumer Health Business to Taisho

Shots: Taisho to acquire BMS’ UPSA Consumer Health Business for $1.6B, in all stock transaction with the put option. The transaction is expected to close in H1’19 The focus of the agreement is to allow BMS to emphasize on its portfolio offering treatments in serious diseases and strengthen Taisho’s OTC platform UPSA develops and delivers medicines in multiple therapeutic […]Read More